Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This two-part study assessed the sustained efficacy of canakinumab in the double-blind Part
II and the ability to taper steroids in the open label Part I.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
Pediatric Rheumatology International Trials Organization